Background: It can be difficult to engage consumers in health decision making. This is
Conclusion: The use of Consumer Impact Statements is particularly suited to palliative care, given that consumers are often otherwise unable to contribute to the public debate.
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Background
Consumer involvement in health policy is highly valued by governments and policy makers 1 , however, there is little empirical evidence about the best way to engage consumers and elicit a consumer perspective [2] [3] . Further study is required to determine which methods of engaging consumers are successful in allowing them to have a voice in making public policy 4 .
In the hospice/palliative care setting, engaging consumers offers considerable challenges. Palliative care patients are, by definition, seriously ill and may be too frail to participate in activities that promote consumer input. However, it is important that the experiences of this group of people be heard to ensure that hospice/palliative care is appropriately funded and that policy frameworks serve consumer needs. Despite a growing interest in making hospice/palliative care services more patient focused and consumer driven, there remains little direction on how this can be achieved systematically 5 . As such, it is incumbent on the palliative care community to attempt to develop ways of engaging hospice/palliative care patients in the on-going dialogue about end of life care that allow for seriously ill people to contribute.
In Australia, the federal Government has subsidised medications since 1944 6 , but there have been limitations associated with the inclusion of medications required in palliative care. Medicines undergo a rigorous assessment process prior to being approved for inclusion in the pharmaceutical benefits scheme, which includes an initial assessment of safety and efficacy by the Therapeutic Goods Administration followed by comparative cost effectiveness. This requires a strong evidence base and there has been no incentive for industry to support developing the evidence base just for indications for use in palliative care given that the market for palliative medications is relatively small and time limited, and most medications where additional evidence is needed are already beyond their period of patent. Therefore, the purpose of this paper is to examine ways that the literature describes consumers' (people requiring palliative care and their carers) contribution to decision making and influencing policy relating to subsidy of pharmaceutical agents used to ameliorate symptoms at the end of life. In particular, the paper aims to explore the potential use of consumer impact statements to assist with medication assessment in the palliative care context.
Search strategy
An extensive search of the literature in the areas of health and medicine was were also searched, with a focus on blogs and on-line fora that describe consumers' experiences.
Results
The literature search revealed almost no information about the use of impact statements in any area of health, and no information was found that related directly to the use of these statements in the area of palliative care or pharmaceutical decision making. Papers were considered relevant if they considered issues of consumer participation in pharmaceutical policy development; consumer input into any aspect of palliative care or the use of impact assessment in policy development. The search of the health-related databases resulted in a small number of articles that were relevant, albeit indirectly, to the issue of Consumer Impact Statement use in a palliative care medications context. As such, this paper presents an overview of related issues and discusses the potential of using impact statements to increase the palliative care consumer voice in pharmaceutical decision making.
Health Impact Assessments
A health impact assessment uses a variety of methods to determine what impact health projects or policies will have on the population most likely to be affected 8 Health impact assessments are widely used in the environmental health area, but can be used to guide any project that may have an impact on the health of a group of people, and are appropriate in areas as diverse as health promotion, environmental health and public health 10 . The main points considered in health impact assessments are the relationship between the project or policy and the health of a population; input of the population that is likely to be affected by the illness (without the ability of service providers or vendors to influence statements); expert opinion and options to minimise health risks and maximise positive health outcomes 11 .
Health impact assessments have five key parts:
i. Screening to assess the need for a health impact assessment;
ii. scoping to determine what is included in the assessment;
iii. assessing health impacts by identifying and analysing potential effects;
iv. decision making, prioritising the issues and developing recommendations; and v. evaluation of the health impact assessment itself, and potentially of the health impacts described as well. 10, 12 In relation to pharmaceutical products, the key need is for decision makers to understand the impact a disease or condition has on the lives of patients and their
caregivers. Governments from a number of countries have developed guidelines for health impact assessments. The Australian Government developed Health Impact Assessment Guidelines primarily for use as part of a wider environmental health impact assessment 13 . Similar guidelines are also available in New Zealand 14 , England 15 and Wales 16 . The guidelines require a health impact assessment to be conducted when developing policies, programs or projects that may impact on the health of a population, however, they are largely focused on environmental health projects such as building or industrial development.
In the public health sphere, health impact statements are used routinely when a project is likely to have an effect on a vulnerable population. The Equity-Focused Health Impact Assessment Framework 17 assists with conducting impact assessments on proposals that are likely to affect minority sectors of the Australian community that may otherwise not be considered. The Antigonish (Canada) Community Health Impact Assessment Tool 18 uses a comprehensive checklist to examine the impact of any health related project on the community, and examines a broad range of issues including child health, environmental health, community demographics, income and social status, social environment and networks, and personal health and health services.
There is less information about how health impact assessment can be used in other sectors of health, including development of public policy 12 .
While health impact assessment is well established in some areas, there is less information about the development of impact statements that describe the effect of a policy or decision on health care consumers, or the implications for patients of a specific condition, disease, or symptom especially in relation to the subsidisation of relevant pharmaceuticals.
In 
Impact Statements in Palliative Care
We have been unable to find any evidence that impact statements are in use in the hospice/palliative care setting. Despite this, there are a number of reasons to consider impact statements as an option for increasing the input of seriously ill people into policy decisions. In particular, the lack of a consumer voice in this area suggests the need for other ways of compiling and presenting information about the experiences of seriously ill people and their caregivers. An impact statement may consider data from a number of sources, including research and other professional literature, personal accounts and data collected by survey, interview or other means. A considerable advantage of developing structured impact statements relating to palliative care is that data collection could be brief in order to minimise patients' and families' burden.
The perceived vulnerability of the palliative care patient group means that there are specific issues to be considered if health impact statements are used as a means of promoting consumer input in hospice/palliative care policy making and practice. While impact statements have the potential to provide a voice to a largely unheard group, the collection of data for the impact statements needs to be considered in terms of ethical issues. The timing of data collection is crucial if the true impact of a symptom experienced by a seriously ill person is being measured, however there are obvious limitations to collecting data in the terminal phase of illness. Therefore, it should be noted that it is unlikely that any impact statement can reflect accurately the entire experiences of someone very close to death.
Palliative care considers the patient and their family as the 'unit of care' 22 . When considering the impact of a condition, disease or symptom it is appropriate to consider the effect on the family and/or caregiver as well. Including the caregivers' perspectives in a consumer impact statement relating to end of life experiences is of benefit for at least two reasons. Firstly, caregivers and close family members may be able to act as a proxy for some key parameters, providing accurate information about the patient's experience [23] [24] . Secondly, the implications of the phenomena being examined on the caregiver and close family is of relevance in this setting, both for their willingness to continue care for this person and the willingness to potentially provide care in the same circumstances again. 
Gathering Evidence for an Impact Statement
There is little information about how best to gather data to inform a health impact statement. While it is likely that the tenets underpinning health impact assessments are suitable for use in the development of consumer impact statements as well, there is a need to consider specific methodologies suitable for collecting information from seriously ill patients. The health literature has a large amount of information about the experiences of patients and their families using different methods and presented in different ways. Each is likely to have some utility in terms of gathering data that are useful for inclusion in an impact statement.
There are lots of quantitative studies that describe conditions or symptoms suffered by people with specific diseases and a plethora of instruments designed to measure symptoms and the impact of symptoms on patients. These are useful for preparing an impact statement as they can offer a range of methods and samples on which to base the impact statement. In addition, they may offer insights into the effects of the condition on the activities of daily living, physical and psychosocial wellbeing or quality of life. For example, a study of symptoms experienced by people with dementia used both patient and caregiver reports of symptoms, using a range of instruments including the Edmonton Symptom Assessment Scale and the End of Life Dementia Scale -Symptom Management 26 . The study showed that the most commonly reported symptoms by patients were pain (42%) and depression (11%) and that caregivers reported cognitive deficit as being most prevalent (47%). Activity disturbance was reported by 15% of caregivers.
Describing the experience of an illness using qualitative research methods such as phenomenology, grounded theory or case study methods is common. Phenomenology in particular may be of benefit when preparing an impact statement because it examines the lived experience of the phenomena in question, generally using one-toone interviews as the method of data collection 27 . Examples of phenomenological studies of the impact of a disease include Ek and Ternestedt's 28 study of people with end-stage chronic obstructive pulmonary disease (COPD) (n=8). The findings of the study described living with COPD as being a life dominated by a lack of physical strength that led to a reduction in activities and in turn social isolation because of the inability to participate in social activities. Participants described emotional distress and feelings of meaningless that accompanied physical limitations. Donovan and
Flynn's study of the experiences of men with breast cancer (n=15) also used a phenomenological approach, using interviews and email conversations to collect data 29 . The findings of this study described the emotional difficulties men experienced suffering what they considered a 'woman's disease' and the effect that this had on their personal relationships and sexuality. The findings of these two studies highlight the strength of using a qualitative method to gather data about living with a specific condition. However, sample sizes are small and sampling techniques are purposive, potentially limiting generalizability of findings.
Systematic and other reviews of literature are useful for preparing impact statements, in that much of the hard work finding appropriate sources of information has already been done. Review papers are able to provide a much deeper insight into the experiences of people with a specific condition, but do not offer the personal insights found in qualitative research papers. Statements such as these could form a useful adjunct to an impact statement and could be used to gather qualitative data about a disease or symptom. However, the nature of the Internet makes it difficult to verify the accuracy and completeness of these accounts and searching can be cumbersome and slow.
The Role of Consumer Impact Statements in Pharmaceutical Policy Development
Preparation of Consumer Impact Statements is likely to be led by the palliative care research community aiming to build a body of evidence to support the need for greater access to medications for people requiring palliative care. The data required for completing a consumer impact statement needs to be collected from a range of sources using a range of methods, so that a comprehensive and balanced account of the impact on patients and their caregivers of a condition, disease or symptom is compiled. As yet, there are few data about the appropriateness of specific methodologies that are suitable for use in this population and it is important that methods used do not prove burdensome to patients and families. The next logical step is to determine ways in which data can be collected to develop impact statements that are suitable for patients and families close to the end of life and that will result in high quality, useful data being available to inform healthcare decision making.
Conclusion
Health impact assessment is becoming more widely accepted as a method of assessing the impact of a government policy, but as yet there is no precedent for using an impact statement in the palliative care setting or pharmaceutical subsidy decision making process. However, it is reasonable to expect that consumers will get a say in the decision that is made and will be able to inform decision makers of their experiences and needs. In the palliative care setting, where people are often seriously ill and perceived to be vulnerable, participating in research is justified if it will benefit the participants and others and, as such, being a part of developing an impact statement is an appropriate way for people at the end of life to contribute to health care decision making. 
